DE602004004883D1 - Vegf-antagonisten zur behandlung von diabetes - Google Patents
Vegf-antagonisten zur behandlung von diabetesInfo
- Publication number
- DE602004004883D1 DE602004004883D1 DE602004004883T DE602004004883T DE602004004883D1 DE 602004004883 D1 DE602004004883 D1 DE 602004004883D1 DE 602004004883 T DE602004004883 T DE 602004004883T DE 602004004883 T DE602004004883 T DE 602004004883T DE 602004004883 D1 DE602004004883 D1 DE 602004004883D1
- Authority
- DE
- Germany
- Prior art keywords
- vegf
- diabetes
- treatment
- vegf antagonists
- blocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45879003P | 2003-03-28 | 2003-03-28 | |
| US458790P | 2003-03-28 | ||
| PCT/US2004/009246 WO2004087206A2 (en) | 2003-03-28 | 2004-03-26 | Methods of treating diabetes by blocking vegf-mediated activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004004883D1 true DE602004004883D1 (de) | 2007-04-05 |
| DE602004004883T2 DE602004004883T2 (de) | 2007-11-15 |
Family
ID=33131825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004004883T Expired - Lifetime DE602004004883T2 (de) | 2003-03-28 | 2004-03-26 | Vegf-antagonisten zur behandlung von diabetes |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7052691B2 (de) |
| EP (1) | EP1608685B1 (de) |
| JP (2) | JP4730909B2 (de) |
| AT (1) | ATE354592T1 (de) |
| AU (1) | AU2004226417B2 (de) |
| BR (1) | BRPI0408749B1 (de) |
| CA (1) | CA2519787C (de) |
| CY (1) | CY1106530T1 (de) |
| DE (1) | DE602004004883T2 (de) |
| DK (1) | DK1608685T3 (de) |
| ES (1) | ES2278333T3 (de) |
| HK (1) | HK1080092A1 (de) |
| MX (1) | MXPA05008972A (de) |
| PL (1) | PL1608685T3 (de) |
| PT (1) | PT1608685E (de) |
| SI (1) | SI1608685T1 (de) |
| WO (1) | WO2004087206A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| EP2586459B1 (de) * | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | VEGF-Antagonistenformulierungen |
| JP5216002B2 (ja) | 2006-06-16 | 2013-06-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤 |
| ES2345596B1 (es) * | 2009-03-26 | 2011-07-13 | Fundacion Progreso Y Salud | Composicion para la prevencion o el tratamiento de la diabetes mellitus. |
| US20100330098A1 (en) * | 2009-06-29 | 2010-12-30 | Kuo Calvin J | Methods to regulate glucose metabolism |
| SG10201802789VA (en) | 2011-01-13 | 2018-05-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| NZ721607A (en) | 2014-01-25 | 2017-05-26 | Chengdu Kanghong Biotechnologies Co Ltd | Fusion protein inhibiting angiogenesis or growth and use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| ITUB20169928A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche per il trattamento del diabete |
| EP4041312A4 (de) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Verfahren zur behandlung einer augenstörung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| NZ514918A (en) * | 1999-04-28 | 2003-11-28 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| DE60019415T2 (de) * | 1999-06-08 | 2006-03-09 | Regeneron Pharmaceuticals, Inc. | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
-
2004
- 2004-03-26 ES ES04758372T patent/ES2278333T3/es not_active Expired - Lifetime
- 2004-03-26 PT PT04758372T patent/PT1608685E/pt unknown
- 2004-03-26 JP JP2006509325A patent/JP4730909B2/ja not_active Expired - Fee Related
- 2004-03-26 PL PL04758372T patent/PL1608685T3/pl unknown
- 2004-03-26 MX MXPA05008972A patent/MXPA05008972A/es active IP Right Grant
- 2004-03-26 EP EP04758372A patent/EP1608685B1/de not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408749A patent/BRPI0408749B1/pt not_active IP Right Cessation
- 2004-03-26 US US10/811,170 patent/US7052691B2/en not_active Expired - Lifetime
- 2004-03-26 DK DK04758372T patent/DK1608685T3/da active
- 2004-03-26 WO PCT/US2004/009246 patent/WO2004087206A2/en active Search and Examination
- 2004-03-26 SI SI200430312T patent/SI1608685T1/sl unknown
- 2004-03-26 AU AU2004226417A patent/AU2004226417B2/en not_active Ceased
- 2004-03-26 DE DE602004004883T patent/DE602004004883T2/de not_active Expired - Lifetime
- 2004-03-26 CA CA2519787A patent/CA2519787C/en not_active Expired - Fee Related
- 2004-03-26 AT AT04758372T patent/ATE354592T1/de active
-
2006
- 2006-03-03 HK HK06102834A patent/HK1080092A1/xx not_active IP Right Cessation
-
2007
- 2007-04-19 CY CY20071100538T patent/CY1106530T1/el unknown
-
2010
- 2010-10-20 JP JP2010235790A patent/JP2011037894A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1080092A1 (en) | 2006-04-21 |
| BRPI0408749B1 (pt) | 2016-10-04 |
| ATE354592T1 (de) | 2007-03-15 |
| ES2278333T3 (es) | 2007-08-01 |
| US20040213787A1 (en) | 2004-10-28 |
| EP1608685A2 (de) | 2005-12-28 |
| SI1608685T1 (sl) | 2007-08-31 |
| JP4730909B2 (ja) | 2011-07-20 |
| EP1608685B1 (de) | 2007-02-21 |
| AU2004226417A1 (en) | 2004-10-14 |
| MXPA05008972A (es) | 2005-11-04 |
| US7052691B2 (en) | 2006-05-30 |
| PL1608685T3 (pl) | 2007-07-31 |
| DE602004004883T2 (de) | 2007-11-15 |
| AU2004226417B2 (en) | 2009-01-22 |
| BRPI0408749A (pt) | 2006-03-28 |
| PT1608685E (pt) | 2007-05-31 |
| CY1106530T1 (el) | 2012-01-25 |
| JP2006521397A (ja) | 2006-09-21 |
| JP2011037894A (ja) | 2011-02-24 |
| WO2004087206A3 (en) | 2004-12-16 |
| DK1608685T3 (da) | 2007-06-11 |
| CA2519787A1 (en) | 2004-10-14 |
| WO2004087206A2 (en) | 2004-10-14 |
| CA2519787C (en) | 2012-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1080092A1 (en) | Vegf antagonists for the treatment of diabetes | |
| ATE321048T1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
| HK1105167A1 (en) | Methods of treating type i diabetes by blocking vegf-mediated activity | |
| DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
| ATE451930T1 (de) | Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis | |
| ATE513550T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| DE602004032340D1 (de) | Verfahren zur behandlung von lentivirusinfektionen | |
| ATE428712T1 (de) | 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60129330D1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
| ATE410235T1 (de) | Behandlung von ballastwasser | |
| WO2005070042A8 (en) | Novel chemical compounds | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE60329000D1 (de) | C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose | |
| DE60229123D1 (de) | Behandlung von fibromyalgie mit pindolol | |
| ATE533769T1 (de) | Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
| DE60229047D1 (de) | Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit | |
| ATE525071T1 (de) | Verbindngen zur hemmung der sap-bindung zur behandlung von osteoarthritis | |
| ATE516813T1 (de) | Verfahren und verbindungen zur behandlung von diabetes | |
| DE602004030167D1 (de) | Chemische behandlung von tierhäuten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8381 | Inventor (new situation) |
Inventor name: WIEGAND, STANLEY, J.W., CROTON-ON-HUDSON, NY 1, US Inventor name: SLEEMAN, MARK, W., MAHOPAC, NY 10541, US |
|
| 8364 | No opposition during term of opposition |